Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 6, 2005 Chuck Saletta	Waiting on Greatness Waiting is often the hardest part of investing. But it's also usually the most lucrative.
The Motley Fool February 24, 2005 Chuck Saletta	Controlling the Carnage Relying on perpetually rosy scenarios can kill a portfolio. Value investing offers a way out.
The Motley Fool January 19, 2005 Chuck Saletta	Why Value Wins How a disciplined, value-focused approach to investing can turn the odds in your favor.
The Motley Fool March 23, 2005 Chuck Saletta	Catching the Hot Potatoes Diversification can protect your portfolio from the worst of a company's stumbles.
The Motley Fool September 30, 2004 W. D. Crotty	Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment.
The Motley Fool March 2, 2005 Chuck Saletta	Why Value Wins How a disciplined, value-focused approach to investing can turn the odds in your favor.
The Motley Fool December 17, 2004 Philip Durell	Three Out-of-Favor Stocks to Consider Contrarian investor David Dreman gets specific in this interview: Fannie Mae... Altria... ConocoPhillips... etc.
The Motley Fool December 14, 2004 Chuck Saletta	Lift Your Lamp for Value It might not seem evident, but there's a strong parallel between Lady Liberty's call and an investor's search for value. Both are looking to accept others' discards.
The Motley Fool December 29, 2004 Chuck Saletta	Three Tens for a Twenty Take advantage of opportunities to get discounted pricing on companies.
The Motley Fool October 4, 2004 Mathew Emmert	Got Merck? The pharmaceutical's investors can't seem to catch a break.
The Motley Fool July 20, 2005 Chuck Saletta	Beat the House at Its Own Game Investing will always be risky. You can't eliminate that, but you can tilt the odds in your favor with value investing.
The Motley Fool March 1, 2006 Rich Duprey	Celebrex Doubles Lawsuit Risk A new study says the Pfizer painkiller doubles the risk of a heart attack. Investors, beware.
The Motley Fool January 5, 2005 Chuck Saletta	Sominex for Your Portfolio Investing is a risky activity. Make sure your stocks don't keep you up at night.
The Motley Fool December 13, 2005 Rich Duprey	Merck's Bitter Pill The first federal Vioxx trial ends with a deadlocked jury, but that's not necessarily good news for the drugmaker, or investors.
The Motley Fool November 12, 2004 Chuck Saletta	Three Magical Words Margin of safety are the three most important words in value investing.
The Motley Fool May 6, 2005 Rich Duprey	A Patient Investor's Guide to Profit One simple virtue can lead you to the right stock at the right price. All too often, investors try to hurry up and climb aboard the latest growth-stock rocket ship only to get burned as it plummets back to Earth.
The Motley Fool October 22, 2004 Chuck Saletta	When Crystal Balls Break Proper diversification is one method by which investors can reduce the risk to their portfolio as a whole without significantly compromising their overall expected returns, making it a key tool for any value investor's kit.
The Motley Fool November 15, 2004 Mathew Emmert	Merck's Silver Lining The government joins the plethora of lawsuit filers, but Merck will survive. Still, the stock remains appropriate for only those investors with a high tolerance for risk and a long-term time horizon.
The Motley Fool January 25, 2005 Stephen D. Simpson	Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today.
The Motley Fool February 23, 2005 Stephen D. Simpson	Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector.
The Motley Fool January 28, 2005 Philip Durell	Tom Gardner Interviews Philip Durell Tom and the author get together to talk value investing.
The Motley Fool January 25, 2006 Tim Hanson	Find the Silver Lining Falling stock prices don't have to be all bad news. While market drops can test your will, it's always best to keep a level head.
The Motley Fool September 29, 2005 Rich Duprey	Feds Find Fraud at Fannie? Investigators find new, "pervasive" evidence of accounting violations at mortgage guarantor Fannie Mae. The stock plunged nearly 11% to a low of $41.71, a level not seen since 1997.
The Motley Fool June 2, 2005 Nick Baker	Fannie and Freddie Face New Rules The mortgage giants may get a tougher regulator, but Bush and Greenspan want more. Investors, take note.
The Motley Fool June 30, 2004 Roger Nusbaum	Freddie's Follies What's next for the mortgage behemoth, Freddie Mac?
The Motley Fool August 22, 2005 Stephen D. Simpson	Vioxx Brings the Pain A jury stings Merck for hefty Vioxx damages, battering shares.
The Motley Fool January 14, 2005 Chuck Saletta	Controlling the Carnage Relying on perpetually rosy scenarios can kill a portfolio. Value investing offers a way out.
The Motley Fool April 11, 2007 Billy Fisher	A Replacement for Vioxx at Merck? Drug company has new pain medication in the pipeline. If Arcoxia is approved despite the long odds against it, it could payoff over the long run for Merck shareholders.
The Motley Fool October 21, 2004 Brian Gorman	Merck Is Down But Not Out The pharma's woes may have silver linings. For now, the company's investors might want to sit tight.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal.
The Motley Fool September 7, 2007 Billy Fisher	Epic Vioxx Victory for Merck Merck scores a major victory in its Vioxx saga in the courtroom as New Jersey's Supreme Court rules against the possibility of a national class action Vioxx lawsuit. Shares react positively.
The Motley Fool November 2, 2005 Richard Gibbons	Exploit the Fearful When the fearful mob is panic selling, you can potentially reap huge profits -- if you can calmly analyze the situation, determine the right path to take, and pick up their shares at a discount.
The Motley Fool July 11, 2008 Tom Hutchinson	The Financial System Is Cracking Banking news: Things got worse in the credit crisis this week as the market speculated that Fannie Mae and Freddie Mac could need a government bailout.
The Motley Fool January 21, 2010 Philip Durell	The Worst Stocks for 2010: Fannie Mae Shareholders should cry Uncle.
The Motley Fool December 17, 2004 W.D. Crotty	Painful Pain Drugs Pfizer joins Merck in the COX-2 inhibitor penalty box. Pfizer's stock, has drifted down since the Vioxx news.
The Motley Fool February 21, 2006 Rick Aristotle Munarriz	Biggest Disappointment: Merck In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: Merck is rich in cash, tradition, and potholes.
The Motley Fool October 7, 2004 Brian Gorman	Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors.
The Motley Fool December 4, 2008 Alex Dumortier	Paulson's New Plan: A Cheap Mortgage for Every Home A new rescue plan for the economy would use nationalized mortgage giants Fannie Mae and Freddie Mac to lower the 30-year fixed mortgage rate down as far as 4.5%, over a full point lower than the current level.
The Motley Fool May 16, 2005 Ellen Dowling	Merck Minds Its Manners The drug giant's handbook for its salespeople has Congress offended. Whether the committee thinks its salespeople are charismatic or just plain con artists, Merck's actions will eventually speak louder than its words for patient investors.
The Motley Fool March 21, 2005 Slaughter & Durell	Stock Madness 2005: First Data vs. Fannie Mae Fannie is ripe for a turnaround, while First Data rides the e-payment wave. What's your call? Play "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness to choose.
The Motley Fool March 17, 2009 Bleeker & Williamson	Who's More to Blame: The SEC or Fannie and Freddie? March Madness series: Which government-ish entity do you choose? The SEC has more than enough complicity in this mess, but Freddie Mac and Fannie Mae were set up to fail from the start.
The Motley Fool December 17, 2004 Bill Mann	Fannie Mae's Institutional Arrogance Pity that Fannie's management decided to test the limits of an implied Federal guarantee. Even if the government did step in and back Fannie and Freddie paper, there's not a chance that it'd back the equity.
The Motley Fool November 18, 2004 Lawrence Meyers	Sympathy for Pfizer The market acts like Vioxx, Bextra, and Celebrex are the same drugs. They're not. Investors should change direction.
BusinessWeek July 30, 2007	Another Risk Factor For Merck Plaintiffs' lawyers are salivating over evidence they hope could support their argument that even patients who used the painkiller for short periods were in danger.
The Motley Fool May 27, 2005 Nick Baker	Mama Always Said You'd Go Blind Urban legends aside, what do new concerns about Viagra and Cialis mean for investors?
The Motley Fool April 10, 2006 Rich Duprey	Merck Splits the Difference The pharmaceutical wins one, loses one in New Jersey Vioxx trials. Investors should expect to see more losses.
BusinessWeek May 13, 2010 Roben Farzad	Rethinking Fannie and Freddie Without overhauling the mortgage giants, reform is unlikely
The Motley Fool January 19, 2005 Bill Mann	Putting Blame Where It Is Due Shorts don't take down companies -- crooked and incompetent executives do. Similarly, those homebuilders who are seeking to put more control on Fannie Mae are not the cause of its problems. They're a result of its actions.
The Motley Fool August 2, 2007 Brian Orelli	98 Lawsuits Down, About 15,000 To Go Merck's Vioxx caseload just got a little smaller, when an appellate court ruled that 98 people from England and Wales could not sue in the U.S. Shares are up on the news.
The Motley Fool May 15, 2008 Tom Hutchinson	Freddie Gets a Boost Freddie Mac's stock soars on news of capital raising.